Rhumbline Advisers Has $3.22 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Rhumbline Advisers decreased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,528 shares of the biopharmaceutical company’s stock after selling 2,613 shares during the quarter. Rhumbline Advisers owned approximately 0.11% of ACADIA Pharmaceuticals worth $3,221,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in ACADIA Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,281 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 3,378 shares in the last quarter. R Squared Ltd bought a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at about $47,000. KBC Group NV grew its stake in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 2,044 shares in the last quarter. SG Americas Securities LLC increased its position in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after acquiring an additional 1,966,607 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its stake in ACADIA Pharmaceuticals by 7.8% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 103,325 shares of the biopharmaceutical company’s stock worth $1,896,000 after purchasing an additional 7,491 shares in the last quarter. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD opened at $19.60 on Friday. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $24.53. The business has a fifty day moving average price of $18.42 and a 200-day moving average price of $16.85. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of 25.13 and a beta of 0.37.

Analyst Ratings Changes

Several equities analysts have weighed in on ACAD shares. Deutsche Bank Aktiengesellschaft assumed coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday. Finally, StockNews.com lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.